A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

NCT00651365 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class

Stopped Early termination due to increase in serum creatinine levels and minimal PD activity.

Conditions

Interventions

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators